A polymorphism in the GALNT2 gene and ovarian cancer risk in four population based case-control studies

International Journal of Molecular Epidemiology and Genetics

Volumn 1, Issue 4, 2010, Pages 272-277

  Terry, Kathryn L ^a   Vitonis, Allison F ^a   Hernandez, Dena ^b   Lurie, Galina ^c   Song, Honglin ^d   Ramus, Susan J ^e   Titus Ernstoff, Linda ^f   Carney, Michael E ^c   Wilkens, Lynne R ^c   Gentry Maharaj, Aleksandra ^e   Menon, Usha ^e   Gayther, Simon A ^e   Pharaoh, Paul D ^d   Goodman, Marc T ^c   Cramer, Daniel W ^a   Birrer, Michael J ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f NONE

Author keywords

MUC1; Ovarian cancer; Polymorphism

Indexed keywords

N ACETYLGALACTOSAMINYLTRANSFERASE; N ACETYLGALACTOSAMINYLTRANSFERASE 2; UNCLASSIFIED DRUG;

ARTICLE; CANCER RISK; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; POPULATION BASED CASE CONTROL STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 78449265758     PISSN: None     EISSN: 19481756     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Gendler SJ and Spicer AP. Epithelial mucin genes. Annu Rev Physiol 1995; 57: 607-634.
2. Ho SB, Niehans GA, Lyftogt C, Yan PS, Cherwitz DL, Gum ET, Dahiya R and Kim YS. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993; 53: 641-651.
3. Fontenot JD, Mariappan SV, Catasti P, Domenech N, Finn OJ and Gupta G. Structure of a tumor associated antigen containing a tandemly repeated immunodominant epitope. J Biomol Struct Dyn 1995; 13: 245-260.
4. Vlad AM, Kettel JC, Alajez NM, Carlos CA and Finn OJ. MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 2004; 82: 249-293.
5. Cramer DW, Titus-Ernstoff L, McKolanis JR, Welch WR, Vitonis AF, Berkowitz RS and Finn OJ. Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 1125-1131.
6. Pinheiro S, Hankinson S, Tworoger S, Rosner B, McKolanis J, Finn O and Cramer D. Anti-MUC1 antibodies and Ovarian Cancer Risk: Prospective Data from the Nurses' Health Studies. Cancer Epidemiol Biomarkers Prev 2010; (in press)
7. Wandall HH, Hassan H, Mirgorodskaya E, Kristensen AK, Roepstorff P, Bennett EP, Nielsen PA, Hollingsworth MA, Burchell J, Taylor-Papadimitriou J and Clausen H. Substrate specificities of three members of the human UDP-N-acetyl-alpha-D-galactosamine:Polypeptide N-acetylgalactosaminyltransferase family, GalNAc-T1, -T2, and -T3. J Biol Chem 1997; 272: 23503-23514.
8. Sellers TA, Huang Y, Cunningham J, Goode EL, Sutphen R, Vierkant RA, Kelemen LE, Frederick-sen ZS, Liebow M, Pankratz VS, Hartmann LC, Myer J, Iversen ES, Jr., Schildkraut JM and Phelan C. Association of single nucleotide polymorphisms in glycosylation genes with risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 397-404.
9. Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY and Goodman MT. Genetic polymorphisms in the Paraoxonase 1 gene and risk of ovarian epithelial carcinoma. Cancer Epidemiol Biomarkers Prev 2008; 17: 2070-2077.
10. Ramus SJ, Vierkant RA, Johnatty SE, Pike MC, Van Den Berg DJ, Wu AH, Pearce CL, Menon U, Gentry-Maharaj A, Gayther SA, Dicioccio RA, McGuire V, Whittemore AS, Song H, Easton DF, Pharoah PD, Garcia-Closas M, Chanock S, Lissowska J, Brinton L, Terry KL, Cramer DW, Tworoger SS, Hankinson SE, Berchuck A, Moorman PG, Schildkraut JM, Cunningham JM, Liebow M, Kjaer SK, Hogdall E, Hogdall C, Blaakaer J, Ness RB, Moysich KB, Edwards RP, Carney ME, Lurie G, Goodman MT, Wang-Gohrke S, Kropp S, Chang-Claude J, Webb PM, Chen X, Beesley J, Chenevix-Trench G and Goode EL. Consortium analysis of 7 candidate SNPs for ovarian cancer. Int J Cancer 2008; 123: 380-388.
11. Terry KL, De Vivo I, Titus-Ernstoff L, Shih MC and Cramer DW. Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk. Cancer Res 2005; 65: 5974-5981.
12. Kotera Y, Fontenot JD, Pecher G, Metzgar RS and Finn OJ. Humoral immunity against a tan-dem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 1994; 54: 2856-2860.
13. Terry KL, Titus-Ernstoff L, McKolanis JR, Welch WR, Finn OJ and Cramer DW. Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 30-35.
14. Phelan CM, Tsai YY, Goode EL, Vierkant RA, Fridley BL, Beesley J, Chen XQ, Webb PM, Chanock S, Cramer DW, Moysich K, Edwards RP, Chang-Claude J, Garcia-Closas M, Yang H, Wang-Gohrke S, Hein R, Green AC, Lissowska J, Carney ME, Lurie G, Wilkens LR, Ness RB, Pearce CL, Wu AH, Van Den Berg DJ, Stram DO, Terry KL, Whiteman DC, Whittemore AS, DiCioccio RA, McGuire V, Doherty JA, Rossing MA, Anton-Culver H, Ziogas A, Hogdall C, Hogdall E, Kruger Kjaer S, Blaakaer J, Quaye L, Ramus SJ, Jacobs I, Song H, Pharoah PD, Iversen ES, Marks JR, Pike MC, Gayther SA, Cunningham JM, Goodman MT, Schildkraut JM, Chenevix-Trench G, Berchuck A and Sellers TA. Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 19: 600-604.
15. Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, Anton-Culver H, Chang-Claude J, Cramer DW, DiCioccio R, Dork T, Goode EL, Goodman MT, Schildkraut JM, Sellers T, Baglietto L, Beckmann MW, Beesley J, Blaakaer J, Carney ME, Chanock S, Chen Z, Cunningham JM, Dicks E, Doherty JA, Durst M, Ekici AB, Fen-stermacher D, Fridley BL, Giles G, Gore ME, De Vivo I, Hillemanns P, Hogdall C, Hogdall E, Iversen ES, Jacobs IJ, Jakubowska A, Li D, Lis-sowska J, Lubinski J, Lurie G, McGuire V, McLaughlin J, Medrek K, Moorman PG, Moysich K, Narod S, Phelan C, Pye C, Risch H, Runne-baum IB, Severi G, Southey M, Stram DO, Thiel FC, Terry KL, Tsai YY, Tworoger SS, Van Den Berg DJ, Vierkant RA, Wang-Gohrke S, Webb PM, Wilkens LR, Wu AH, Yang H, Brewster W, Ziogas A, Houlston R, Tomlinson I, Whittemore AS, Ross-ing MA, Ponder BA, Pearce CL, Ness RB, Menon U, Kjaer SK, Gronwald J, Garcia-Closas M, Fasching PA, Easton DF, Chenevix-Trench G, Berchuck A, Pharoah PD and Gayther SA. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 2009; 41: 996-1000.
16. Hirschhorn JN, Lohmueller K, Byrne E and Hirschhorn K. A comprehensive review of genetic association studies. Genet Med 2002; 4: 45-61.
17. Ioannidis JP, Ntzani EE, Trikalinos TA and Con-topoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet 2001; 29: 306-309.
18. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L and Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004; 96: 434-442.
19. Dickson SP, Wang K, Krantz I, Hakonarson H and Goldstein DB. Rare variants create synthetic genome-wide associations. PLoS Biol 8: e1000294.
20. Via M, Gignoux C and Burchard EG. The 1000 Genomes Project: new opportunities for research and social challenges. Genome Med 2: 3.